The quarter met the limited earnings expectation. Trevi reported second-quarter EPS of -$0.11, matching the published consensus of roughly -$0.11; as a clinical-stage company, it has no meaningful product revenue to create a revenue beat or miss.
| Metric | Q2 2026 | Q2 2025 | Market expectation |
|---|---|---|---|
| Net loss | $17.8 million | $12.3 million | — (Statement of Operations Data) |
| Basic and diluted loss per share | $0.11 loss | $0.09 loss | $0.11 loss (published consensus) |
| R&D expense | $15.2 million | $9.4 million | — (Statement of Operations Data) |
| G&A expense | $5.4 million | $4.3 million | — (Statement of Operations Data) |
| Cash, cash equivalents and marketable securities | $318.9 million | — | — (Financial Highlights) |
Clinical execution was the substantive update, but largely on plan rather than a surprise. Trevi initiated the Phase 3 OCEAN-1 trial in IPF-related chronic cough and the Phase 2b LAKE trial in refractory chronic cough during the quarter, while maintaining its plan to start OCEAN-2 in the third quarter of 2026. That advances the program toward major data readouts in the second half of 2027 and first half of 2028, but the filing does not add efficacy data or accelerate those timelines (Recent Business Highlights — IPF-Related Chronic Cough; Refractory Chronic Cough).
The balance sheet reduces near-term financing pressure, but the improvement was already visible. Cash and investments totaled $318.9 million after the April financing produced approximately $162.3 million in net proceeds, and management now expects funding into 2030. That supports development through potential approval in IPF-related cough and through Phase 3 in non-IPF ILD, although the stated runway excludes commercial launch costs and a future Phase 3 RCC trial (Financial Highlights).
Spending is rising as the pipeline moves into late-stage testing. R&D increased 61% year over year to $15.2 million and total operating expenses rose to $20.5 million from $13.7 million, reflecting the OCEAN-1, LAKE, OCEAN-2 and NDA-support activities. The larger loss is therefore consistent with planned trial expansion rather than an unexpected cost overrun, but it also shows that the cash runway depends on continued disciplined execution (Statement of Operations Data; Financial Highlights).
Net read: operationally constructive, but not a clear beat. The company delivered the milestones it had already telegraphed and matched the published EPS bar; the main incremental benefit is greater visibility into trial execution and funding capacity, not new clinical evidence. That supports a mixed assessment versus expectations rather than a positive surprise.
Read the original 8-K on SEC EDGAR ↗